# Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

Study · id `cardio:ct-nct02597127` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02597127](<https://clinicaltrials.gov/study/NCT02597127>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02597127

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 501 participants.

## Technical summary

Registry record NCT02597127. Randomized; double masking; primary purpose treatment. Start 2016-01 (registry gives no type); primary completion 2017-06-07 (actual). Results posted on 2019-05-17.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 501 participants (enrolled count; ClinicalTrials.gov record NCT02597127, source copy `cardio:ctgov-nct02597127-2019-05-17`, retrieved 2026-10-26)
- Start date: 2016-01 (registry gives no type) (ClinicalTrials.gov record NCT02597127, source copy `cardio:ctgov-nct02597127-2019-05-17`, retrieved 2026-10-26)
- Primary completion: 2017-06-07 (actual) (ClinicalTrials.gov record NCT02597127, source copy `cardio:ctgov-nct02597127-2019-05-17`, retrieved 2026-10-26)
- Completion: 2017-06-07 (actual) (ClinicalTrials.gov record NCT02597127, source copy `cardio:ctgov-nct02597127-2019-05-17`, retrieved 2026-10-26)
- Results first posted: 2019-05-17 (ClinicalTrials.gov record NCT02597127, source copy `cardio:ctgov-nct02597127-2019-05-17`, retrieved 2026-10-26)
- Countries: United States; Canada; Germany; Netherlands; United Kingdom (ClinicalTrials.gov record NCT02597127, source copy `cardio:ctgov-nct02597127-2019-05-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02597127-2019-05-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)
- Acronym: ORION-1
- Condition: Atherosclerotic Cardiovascular Disease
- Condition: Familial Hypercholesterolemia
- Condition: Diabetes
- Intervention (Drug): ALN-PCSSC
- Intervention (Drug): Normal Saline
- Lead sponsor: The Medicines Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Familial hypercholesterolemia (`cardio:familial-hypercholesterolemia`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: The Medicines Company (`cardio:org-the-medicines-company`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1 (`cardio:pubmed-29735484`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial (`cardio:pubmed-30487231`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial (`cardio:pubmed-31553410`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c95650a58cd08a10e9d66ff5391fb614e10ad9298bdb8da17455528133dfa9f0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
